WHO to decide on Bharat Biotech’s Covaxin clearance in October

By Sumit Blogs -

The WHO will take a decision on Bharat Biotech’s Covaxin for granting Emergency Use Listing (EUL) in October. While the rolling review started in July, the WHO document on the evaluation of EUL for Covid vaccines, the decision for Covaxin will be taken in October.

Soumya Swaminathan, WHO’s chief scientist, told ET that the “process is ongoing”. The latest ‘Status of COVID-19 vaccines within WHO EUL/PQ evaluation process’ guidance document dated September 29 on the WHO website said that the decision date for Bharat Biotech’s Covaxin is “October 2021”.

The WHO said it began rolling data of the vaccine on July 6.

On Tuesday the company said that it was diligently working with the World Health Organisation (WHO) to obtain EUL at the earliest.

It said that it was not “appropriate to speculate” on the regulatory approval process and the timelines.

“As a responsible manufacturer with past approvals for our other vaccines, we do not find it appropriate to speculate or comment on the regulatory approval process & its timelines,” it said.

The company said it will make announcements to indicate the availability of regulatory approvals at an appropriate time.

“We request media organizations to exercise restraint while reporting on public health-related issues and timelines, as it has an impact on millions of lives and livelihoods,” it further said.

The World Health Organisation panel is likely to meet in the first week of October to review Covaxin for granting EUL, a move that will allow people inoculated with Bharat Biotech’s Covid-19 vaccine to travel abroad without restrictions.

The WHO global advisory committee on vaccine safety will assess immunogenicity, vaccine safety and vaccine effectiveness of Covaxin, a crucial step for granting EUL, people in the know told ET.

An emergency approval from the WHO will allow Bharat Biotech to export Covaxin and enable easy international travel of people who have received this vaccine.

The EUL pathway involves a rigorous assessment of clinical trial data as well as additional data on safety, efficacy, quality, and a risk management plan. Bharat Biotech had in June presented its Phase 3 clinical trials data, demonstrating 77.8% efficacy, to the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).

The WHO has so far approved Covid-19 vaccines of Pfizer-BioNTech, AstraZeneca-SK Bio/Serum Institute of India, Johnson & Johnson-Janssen, Moderna, and Sinopharm for emergency use.

Credits – Source – https://ift.tt/39TGaRv

The post WHO to decide on Bharat Biotech’s Covaxin clearance in October appeared first on Stay in Gurgaon.

Comments

Post a Comment

Popular posts from this blog

Flat sale of flu drugs hints at no unusual rise in infections

By Sumit Blogs -
Image
By Economic Times – Flat sale of flu drugs hints at no unusual rise in infections Industry executives and chemists said the April sales data showed a month-on-month decline of 30-40%. But even though the lockdown is seen to be impacting sales of most drugs, the pattern for medicines for infections and flus is no different.Last Updated: Apr 30, 2020, 11.23 AM ISTAgenciesExperts said the decline in sales was primarily because of the lockdown and other restrictions which forced people to stay indoors. (This story originally appeared in on Apr 30, 2020)NEW DELHI: Sales of anti-infectives (antibiotics and antivirals), respiratory drugs, painkillers and analgesics — some key medicines used for influenza-like illnesses — have remained mostly unchanged in last three months (January to March), partly explained by the lockdown but also indicating no unusual rise in flu-type infections that might point to a wider and undetected spread of Covid-19. Sales of most medicines, including this set of
Read more

10YearsForSimha: Reasons behind film’s success

By Sumit Blogs -
Image
By Times of India – 10YearsForSimha: Reasons behind film’s success TIMESOFINDIA.COM | Last updated on – Apr 30, 2020, 06:00 ISTclose01/6Take a look at the reasons behind the film’s successDirected by Boyapati Srinu, the 2010 film Simha was a game-changer among Tollywood films that was lauded, not only for Nandamuri Balakrishna’s intense performance in the dual role but also the gripping narration of the filmmaker. Balayya and Nayanthara were seen on the big screen for the first time ever in the film. The action drama made a special place in the hearts of the audience because of its simple storytelling, superhit songs and unbeatable chemistry between the lead pair. The movie has completed a decade, but the essence is as fresh as it was back then. As the film clocks 10 years of its release, find out the reasons behind the massive success of the Balakrishna starrer.readmore02/6​Boyapati Srinu’s gripping narrationBefore Simha, Boyapati Srinu had delivered Bhadra (2005) and Tulasi (2007),
Read more

Hrithik-Saif’s Vikram Vedha hits a roadblock

By Sumit Blogs -
Image
The stage was about to be set for Hrithik Roshan and Saif Ali Khan’s ‘Vikram Vedha’ in Mumbai’s Film City. The material had reached. The artisans had been hired. But the lights have now been dimmed. Madhavan and Vijay Sethupathi’s hit movie Vikram Vedha’s Hindi remake will not go on floors by mid-July as per the original plan. The new delta virus of COVID has sent shudders down many spines and many films which were being laid out on an expansive scale have been either held back or shifted their shoots abroad. The first schedule of this Hrithik-Saif movie will now be shot abroad. A source says, “The Mumbai schedule will be done but later.” Adds the source, “It’s a call that was taken yesterday. It wasn’t an easy call to take, no doubt, but the fact that it’s going to be a costly set made the makers take the safer route rather than be sorry later.” When contacted, General Secretary of FWICE (Federation of Western India Cine Employees), Ashok Dubey, confirmed that the makers of ‘V
Read more